Your browser doesn't support javascript.
loading
Antitachycardia pacing success in implantable cardioverter-defibrillators by patient, device, and programming characteristics.
Sterns, Laurence D; Auricchio, Angelo; Schloss, Edward J; Lexcen, Dan; Jacobsen, Luke; DeGroot, Paul; Molan, Amy; Kurita, Takashi.
Afiliación
  • Sterns LD; Vancouver Island Arrhythmia Clinic, Victoria, British Columbia, Canada. Electronic address: LDSterns@gmail.com.
  • Auricchio A; Division of Cardiology, Istituto Cardiocentro Ticino, Lugano, Switzerland.
  • Schloss EJ; The Christ Hospital, Cincinnati, Ohio.
  • Lexcen D; Medtronic Inc., Mounds View, Minnesota.
  • Jacobsen L; Medtronic Inc., Mounds View, Minnesota.
  • DeGroot P; Medtronic Inc., Mounds View, Minnesota.
  • Molan A; Medtronic Inc., Mounds View, Minnesota.
  • Kurita T; Division of Cardiology, Department of Medicine, Kindai University School of Medicine, Osaka, Japan.
Heart Rhythm ; 20(2): 190-197, 2023 02.
Article en En | MEDLINE | ID: mdl-36272710
ABSTRACT

BACKGROUND:

Antitachycardia pacing (ATP) is an established implantable cardioverter-defibrillator (ICD) therapy that terminates ventricular tachycardias (VTs) without painful ICD shocks. However, factors influencing ATP success are not well understood.

OBJECTIVE:

The purpose of this study was to examine ATP success rates by patient, device, and programming characteristics.

METHODS:

This retrospective analysis of the PainFree SmartShock Technology study included spontaneous ATP-treated monomorphic VT episodes. ATP success rates were calculated for various factors. Also, the relationship of ATP programming on shock burden and syncope were investigated.

RESULTS:

Of the 2770 enrolled patients (2200 [79%] male; mean age 65 years), 1699 (61%) received an ICD and 1071 (39%) a cardiac resynchronization therapy - defibrillator. ATP had >80% rate of success for terminating VTs overall, with similar rates observed between ICD and cardiac resynchronization therapy - defibrillator devices (82.2% vs 80.3%, respectively; P = .81) as well as between primary and secondary prevention patients with ICDs (77.2% vs 83.9% respectively; P = .25). Arrhythmias with a median cycle length of ≥320 ms had a significantly higher ATP success rate (88.0%; 95% confidence interval 84.8%-90.6%). The cumulative percentage of ATP success increased from 71% at 1 ATP sequence delivered to 87% at ≥8 sequences delivered. Programming more ATP sequences was associated with lower shock burden (P = .0005). There was no evidence that more sequences were associated with higher rates of syncope (P = .16).

CONCLUSION:

Delivering more ATP sequences resulted in a higher overall success of terminating VTs, while programming more ATP was associated with decreased shock burden and no evidence of increased syncope or acceleration. This suggests that more ATP sequences should be programmed when possible, but confirmation in prospective studies will be necessary.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Taquicardia Ventricular / Desfibriladores Implantables / Terapia de Resincronización Cardíaca Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Heart Rhythm Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Taquicardia Ventricular / Desfibriladores Implantables / Terapia de Resincronización Cardíaca Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Heart Rhythm Año: 2023 Tipo del documento: Article